Biological properties of an initial degradation product of insulin by insulin-degrading enzyme. 1989

K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
Second Department of Internal Medicine, Kobe University School of Medicine, Japan.

We previously reported on the degradation of monocomponent porcine insulin by affinity-purified pig skeletal muscle insulin-degrading enzyme (IDE) and on the detection and HPLC separation of the initial degradation product (peak VI). Using relatively high concentration of insulin, peak VI appeared rapidly at 30 sec of incubation, whereas other peaks were not detected within 5 min of incubation. Performate oxidation studies suggested that peak VI is composed of a cleaved A-chain and an intact B-chain. To assess whether the initial degradation product of insulin generated by IDE preserves biological properties, we analyzed several insulin-like activities of peak VI. It had a hypoglycemic effect on rats. In vitro, it bound to the insulin receptors of rat adipocytes and stimulated glucose oxidation there. It also strengthened insulin receptor kinase activity in insulin receptors from rat liver and human placenta. Its biological potency, however, was 1/40th to 1/160th that of insulin itself. This is probably due to reduced affinity for the insulin receptor, since it had 2.5% of insulin's ability to both bind to the receptor and stimulate glucose oxidation. Moreover, peak VI had all of insulin's agonistic effect on glucose oxidation when used at a higher concentration. On the other hand, cross-linking analysis suggested that peak VI preserves almost the same affinity for IDE as does insulin. These results suggest that pig skeletal muscle IDE may cleave peptide bonds within the A-chain early in insulin degradation, generating peak VI; this then serves as the next substrate of IDE while exerting reduced insulin-like activity, and peak VI is converted to several relatively low mol wt products.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007339 Insulysin An enzyme the catalyzes the degradation of insulin, glucagon and other polypeptides. It is inhibited by bacitracin, chelating agents EDTA and 1,10-phenanthroline, and by thiol-blocking reagents such as N-ethylmaleimide, but not phosphoramidon. (Eur J Biochem 1994;223:1-5) EC 3.4.24.56. Insulinase,Insulin Protease,Insulin Proteinase,Insulin-Degrading Enzyme,Enzyme, Insulin-Degrading,Insulin Degrading Enzyme,Protease, Insulin,Proteinase, Insulin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat

Related Publications

K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
November 1988, Nihon Naibunpi Gakkai zasshi,
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
November 2000, The Journal of biological chemistry,
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
March 2011, PloS one,
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
August 1990, Biochemical and biophysical research communications,
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
April 1991, Diabetes,
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
April 2009, Annals of the New York Academy of Sciences,
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
February 2010, The protein journal,
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
October 1991, Molecular endocrinology (Baltimore, Md.),
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
May 2018, Medical sciences (Basel, Switzerland),
K Yonezawa, and K Yokono, and K Shii, and J Hari, and S Yaso, and T Sakamoto, and Y Kawase, and H Akiyama, and S Taketomi, and S Baba
June 2003, The Journal of endocrinology,
Copied contents to your clipboard!